Whilst in silico medicine isn't explicitly mentioned in the Regulation, this Programme could represent a potential funding opportunity for VPH and may make better use of the wealth of health data collected in each Member State.
The issues of relevance for VPH are contained within the thematic priority relating to Contributions to innovative, efficient and sustainable health systems. The most pertinent points referenced include the following:
Concerning its broad objectives, the Regulation specifies four principal goals to be attained through the prospective implementation of the Program:
In terms of the final budget allocated to the Program’s implementation, the recently adopted Regulation sets the financial package for the 2014-2020 period in €449,334 million. When providing the main guidelines on how the funds will be assigned, the Regulation specifies that funding could take the form of grants or public procurement. Developing that specific issue, the Regulation establishes that grants will be awarded for pertinent projects co-financed by the competent Member-State’s health authorities or by relevant public bodies, NGOs or private bodies, being the latter exclusively understood as health institutions, research centres and universities.
The European Commission is to set the different priority actions to be undertaken and include an indicative allocation of financial resources to be provided for the realisation of the aforementioned actions. The Member States will also have their part in the implementation of the plan through the designation of National Focal Points that will facilitate and promote the coordination of initiatives in line with the Program’s objectives.
The full Regulation can be accessed here.